



COVID-19 VACCINES

ISV VIRTUAL CONGRESS SERIES

1st Congress
June 22, 2020

Registration

www.ISVCongress.org

CONTACT

PHONE:
1-508-856-6791

EMAIL:
Info@ISVCONGRESS.ORG

Program June 22, 9:00am – 12:00 noon (ET)

9:00 am Welcome and Introductions
Chairs: Linda Klavinskis & Shan Lu, ISV

Opening Session (20 min talks + 5 min Q&A)

Overview, Chair: Shan Lu, ISV

9:05am Kwok-Yung Yuen, The University of Hong Kong
Overview of COVID-19

9:30am Nick Jackson, CEPI
Overview of COVID-19 vaccine development

Scientific Session One (18 min talks + 7 min Q&A)

Nucleic Acid Vaccines, Chair: Margaret Liu, ISV

9:55am Kate Broderick, Inovio Pharmaceuticals
Advantages of a DNA-based Approach to the
Development of a COVID-19 Vaccine

10:20am Barney Graham (VRC/NIAID/NIH)
Rapid COVID-19 Vaccine Development Enabled
by Prototype Pathogen Preparedness

Viral Vector Vaccines, Chair: Linda Klavinskis, ISV

10:45am Sarah Gilbert, University of Oxford
Rapid Progress with Development of ChAdOx1
nCoV-19

11:10am Tao Zhu, CanSino Biological
Development of Adenovirus Vector based
COVID-19 Vaccine

Scientific Session Two (25 min panel discussion)

Challenges for COVID-19 vaccines development

Moderator: David Weiner, ISV

11:35am Peter Openshaw, Imperial College London
Stanley Perlman, University of Iowa
Stanley Plotkin, VaxConsult

- Are human challenge studies acceptable?
- Safety concerns and suboptimal antibody responses

Wrap up and announcement of 2nd ISV Virtual Congress on COVID-19 Vaccines

12 noon Closing remarks
Margaret Liu, ISV

The virtual congress will be run by Microsoft Teams.





COVID-19 VACCINES

ISV VIRTUAL CONGRESS SERIES

2nd Congress
July 21, 2020

Registration

www.ISVCongress.org

CONTACT

PHONE:
1-508-856-1179

EMAIL:
Info@ISVCongress.org

Program July 21, 9:00am – 12:00PM (ET)

9:00 am Welcome and Introductions
Chair: Shan Lu, UMass Medical School/ISV
Linda Klavinskis, King's College London/ISV
Introduction of ISV Virtual Congress

Opening Session (20 min talks + 5 min Q&A)

Chair: Denise Doolan, James Cook University/ISV
9:05am Larry Corey, Fred Hutchinson Cancer Res. Center
COVID Vaccine Planning: The USG Approach
9:30am Marion Gruber, US FDA
Regulatory Considerations in the Development
and Licensure of COVID-19 Vaccines

Scientific Session One (18 min talks + 7 min Q&A)

Part I: Protein and Inactivated Vaccines

Chair: Manon Cox, NextWaveBio/ISV
9:55am Greg Glenn, Novavax
Progress with the Full Length Recombinant Spike
Protein Nanoparticle Vaccine
10:20am George Gao, China CDC
Development of Inactivated COVID-19 Vaccines

Part II: Viral Vector and RNA Vaccines

Chair: Linda Klavinskis, King's College London/ISV
10:45am Hanneke Schuitemaker, J&J/Janssen
The Development of an Ad26-based
SARS-CoV-2 Vaccine
11:10am Kena Swanson, Pfizer
RNA Based COVID-19 Vaccines

Scientific Session Two (25 min panel discussion)

Challenges for COVID-19 Vaccines Development:

The Roles of Animal Models

Moderator: Stanley Perlman, University of Iowa
11:35am Bart Haagmans, Erasmus University
Vincent Munster, RML/NIH
Linda Saif, The Ohio State University

Wrap up and Announcement of 3rd ISV Virtual Congress on COVID-19 Vaccines

12:00PM Shan Lu, ISV

ISV Virtual Congress Series Co-Chairs
Linda Klavinskis, Margaret Liu, Shan Lu / ISV
Senior Advisor
Nick Jackson / CEPI





COVID-19 VACCINES

ISV VIRTUAL CONGRESS SERIES

3rd Congress
Aug 25, 2020

Registration

www.ISVCongress.org

CONTACT

PHONE:
1-508-856-1179

EMAIL:
Info@ISVCongress.org

Program Aug 25, 9:00am – 12:00 noon (ET)

9:00 am Welcome and Introductions
Chair: Shan Lu, UMass Medical School/ISV
Linda Klavinskis, King's College London/ISV
Introduction of ISV Virtual Congress

Opening Session (20 min talks + 5 min Q&A)

Chair: Shan Lu, ISV
9:05am Myron Cohen, UNC-Chapel Hill
mAbs for COVID-19: Treatment and Prevention
9:30am Lynda Stuart, Bill & Melinda Gates Foundation
COVID-19 Vaccine: How We Win the Race to
Billions of Doses

Scientific Session One (18 min talks + 7 min Q&A)

Part I: Protein Vaccines

Chair: Xavier Saelens, University of Ghent/ISV
9:55am Keith Chappell, The University of Queensland
Molecular Clamp Stabilized Recombinant Protein
Subunit Vaccine for COVID-19
10:20am John Shiver, Sanofi-GSK
Recombinant and mRNA Vaccine Candidates
Against COVID-19

Part II: Novel Vaccine Technologies

Chair: Anna-Lise Williamson, University of Cape Town/ISV
10:45am Jacqueline Miller, Moderna
Moderna's Coronavirus Vaccine: Early Clinical Data
and the COVE Phase III Efficacy and Safety Study
11:05am Brian Ward, Medicago
Development of Plant-Derived SARS-CoV-2 Virus-
Like Particle (CoVLP) Vaccine

Scientific Session Two (30 min panel discussion)

The Role of T and B Cell Responses and Vaccine Assay Standards
for Determining Efficacy
Moderator: Margret Liu, ProTherImmune/ISV
11:30am Alessandro Sette, La Jolla Institute for Immunology
Michel Nussenzweig, The Rockefeller University
Neil Almond, NIBSC

Wrap up and Future ISV Virtual Congresses

12:00pm Linda Klavinskis, ISV

ISV Virtual Congress Series Co-Chairs

Linda Klavinskis, Margaret Liu, Shan Lu / ISV
Senior Advisors

Nick Jackson / CEPI, Susan Barnett / BMGF

